Evidence map›Paper›PMID 29725397›Full record

ArticleOncology letters2018

Diallyl disulfide effect on the invasion and migration ability of HL-60 cells with a high expression of DJ-1 in the nucleus through the suppression of the Src signaling pathway.

Ran Liu, Ye-Ning Yang, Lan Yi, Jing Qing, Qing-Ye Li, Wen-Song Wang, Juan Wang, Yu-Xian Tang, Hui Tan

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Organosulfur Compounds: Potential Therapeutics for Parkinson's Disease.CNS & neurological disorders drug targets · 2026
    Review
  2. Diallyl disulfide in oncotherapy: molecular mechanisms and therapeutic potentials.Apoptosis : an international journal on programmed cell death · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Biological Functions of Diallyl Disulfide, a Garlic-Derived Natural Organic Sulfur Compound.Evidence-based complementary and alternative medicine : eCAM · 2021
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ran LiuCancer Research Institute, Key Laboratory of Tumor Cellular and Molecular Pathology, College of Hunan Province, University of South China, Hunan 421001, P.R. China.
Ye-Ning YangDepartment of Pathology, The First People's Hospital of Youxian, Youxian, Hunan 412300, P.R. China.
Lan YiCancer Research Institute, Key Laboratory of Tumor Cellular and Molecular Pathology, College of Hunan Province, University of South China, Hunan 421001, P.R. China.
Jing QingCancer Research Institute, Key Laboratory of Tumor Cellular and Molecular Pathology, College of Hunan Province, University of South China, Hunan 421001, P.R. China.
Qing-Ye LiCancer Research Institute, Key Laboratory of Tumor Cellular and Molecular Pathology, College of Hunan Province, University of South China, Hunan 421001, P.R. China.
Wen-Song WangCancer Research Institute, Key Laboratory of Tumor Cellular and Molecular Pathology, College of Hunan Province, University of South China, Hunan 421001, P.R. China.
Juan WangCancer Research Institute, Key Laboratory of Tumor Cellular and Molecular Pathology, College of Hunan Province, University of South China, Hunan 421001, P.R. China.
Yu-Xian TangCancer Research Institute, Key Laboratory of Tumor Cellular and Molecular Pathology, College of Hunan Province, University of South China, Hunan 421001, P.R. China.
Hui TanCancer Research Institute, Key Laboratory of Tumor Cellular and Molecular Pathology, College of Hunan Province, University of South China, Hunan 421001, P.R. China.
University of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study examined the effect of diallyl disulfide (DADS) on the invasion and migration ability of HL-60 cells with a high expression of parkinsonism associated deglycase (DJ-1) in the nucleus (HHDN), and its molecular mechanism. A western blot assay was used to measure the effects of DADS and an Src inhibitor on the expression of DJ-1 and the Src signal pathway in HHDN. The effects of DADS and Src inhibitors on the invasion and migration ability of HHDN was detected using Transwell migration and invasion chamber experiments. The experiments were divided into three groups: A control group (HL-60 cells), an empty vector group and a high expression group (HHDN cells). Western blot assays revealed that the expression of DJ-1 in HHDN was inhibited in a time-dependent manner following treatment with DADS for 24, 48 and 72 h. Following DADS treatment, the expression of phosphorylated Src (p-Src) and phosphorylated Fak (p-Fak) were significantly decreased in all groups compared with the untreated groups, however the expression level of Src, Fak and integrin did not change significantly. Western blot analysis results revealed that following treatment with DADS and Src inhibitor, the expression levels of p-Src and p-Fak significantly decreased in all three groups compared with untreated groups, whereas the expression levels of Src, Fak and integrin did not change significantly. The expression of DJ-1 in HHND was inhibited in time-dependent manner following treatment with DADS and Src inhibitor for 24, 48 and 72 h. Transwell migration and invasion assay results revealed that DADS and Src inhibitors may suppress migration and invasion in leukemic cells, and a combination of the two treatments may result in more efficient suppression. DADS may downregulate DJ-1-mediated invasion and migration in leukemic cells through suppressing the Src-Fak-Integrin signaling pathway, and the Src inhibitor may enhance the antitumor effect of DADS.

Indexed as

diallyl disulfideinvasionleukemiamigrationparkinsonism associated deglycaseSrcSrc signaling pathway

Identifiers

PMID29725397
PMCPMC5920463
OpenAlexW2791124865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.